Alkem Laboratories Ltd

- Alkem Laboratories is commissioning a CDMO biologic plant (Enzene plant) in the U.S., expected to be operational by Q4 FY2025 or Q1 FY2026. The plant focuses on preclinical to clinical small production, with a capex of around INR 450 crores. - The company is incurring some non-material expenses currently on this plant, which are not capitalized yet. - For strategic investments, Alkem has shifted from parking funds in fixed deposits to investments in AAA+ rated Non-Convertible Debentures (NCDs) and mutual funds, enabling liquidity for potential M&A opportunities. - Alkem is actively looking for M&A opportunities that are strategic, where they can add value and build synergies; they target IRRs above 14-15%, with a cost of capital around 12%. - The company has also invested about INR 30 crores in a strategic but low-risk company investment.

- Domestic growth expected at 8%-9% annually, with Q4 anticipated to be stronger than earlier quarters. - Chronic segment projected to grow faster than the acute segment, increasing its share in the portfolio over the next 3 years. - ROW (Rest of the World) markets, excluding U.S. and Chile, showed 30% growth in Q2, with further market filings and strategic partnerships expected to sustain this growth in 2-3 years. - U.S. business expected to improve in H2 FY '25 after supply chain challenges caused volume declines; mid-single-digit erosion anticipated annually but better performance expected going forward. - New product launches and biosimilars pipeline aimed at driving long-term growth, including plans for 2-3 key biosimilars globally over 5 years. - Overall, revenue growth for FY '25 expected to be mid-single-digit due to earlier U.S. struggles but improving across other markets.

- The company targets improving EBITDA margins by at least 100 basis points annually. - For FY '25, EBITDA margin guidance is between 18.5% to 19%, with a 100 basis points improvement expected over the previous year. - Net profit for Q2 FY '25 grew by 11% year-on-year, and H1 net profit grew 36% Y-o-Y to INR 12,338 million. - The company anticipates mid-single-digit top-line growth for the full year despite H1 challenges, especially in the U.S. market. - Domestic market growth is expected at 8-9% annually, with Q4 anticipated to deliver stronger growth. - Margin expansion driven by a better product mix, cost controls, and higher-margin international markets growth (ROW). - Focus on strategic M&As to accelerate growth, targeting assets with IRR above 14-15% with strategic synergy benefits. - Enzene U.S. plant expected to break even in its first year, contributing to future profitability.

- The Enzene U.S. plant is progressing as planned, with expected production start by Q4 FY25 to Q1 FY26. - The company has already started receiving queries and some orders for the Enzene plant even before production begins. - Vikas Gupta mentioned an existing order book based on the plant's progress, indicating a promising pipeline. - While detailed specifics on the full orderbook size are not disclosed, the management expressed optimism about upcoming launches and order inflow. - Focus on new product launches, including a product with 180-day exclusivity and sacubitril-valsartan, suggests growing pending orders for U.S. market.

- There is no mention in the transcript of any current or planned fundraising through debt or equity. - The company has increased its cash position significantly, nearly doubling it to around INR 4,250 crores as of September 30, 2024. - The raised cash is being strategically invested in marketable instruments to maintain liquidity, partly to support potential M&A opportunities. - Management emphasizes a preference for strategic acquisitions rather than purely financially motivated investments. - No indications of immediate capital raising via debt or equity were discussed during the call.